GlassScriptPhysician profile
Michael Bobrov
NPI 1306372289
$741.57
in general payments reported to CMS, 2019-2025
13 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.64 · 2021: $155 · 2022: $39.43 · 2023: $137 · 2024: $214 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $427.76 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $119.07 | 2024 | Ultomiris, Soliris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.53 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $113.25 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $107.68 | 2022-2025 | Farxiga, Lokelma |
| Pfizer INC. | $65.92 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.51 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $40.21 | 2021-2025 | Eliquis |
| Smith+Nephew, INC. | $38.83 | 2025 | Collagenase Santyl |
| Genzyme Corporation | $27.55 | 2024 | |
| Gilead Sciences, INC. | $20.52 | 2024 | |
| La Jolla Pharmaceutical Company | $20.30 | 2024 | Xerava |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.27 | 2021 | |
| Acutus Medical, INC. | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bobrov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.